Nitroglycerine use preceding PCI for ACS tied to lower BP and adverse clinical outcomes in elderly
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-06 16:00 GMT | Update On 2024-02-07 07:23 GMT
Advertisement
Primary care for acute coronary syndrome (ACS) typically involves administering nitroglycerin (GTN). However, it remains unclear whether GTN use before primary percutaneous coronary intervention (PCI) is related to major adverse cardiovascular events (MACE) in the era of changing patient characteristics and advancements in ACS management, which include advances in PCI and optimal medical therapy.
According to a recent study published in BMJ Open Heart Journal, the use of GTN preceding primary PCI for ACS was found to have an independent association with the incidence of MACE within one year. Additionally, the GTN group had a significantly higher incidence of MACE in comparison to the non-GTN group in elderly patients who are aged ≥75 years.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.